Staidson (Beijing) BioPharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Staidson (Beijing) BioPharmaceuticals's earnings have been declining at an average annual rate of -50.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been declining at an average rate of 8.2% per year.
Key information
-50.6%
Earnings growth rate
-50.4%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | -8.2% |
Return on equity | -34.4% |
Net Margin | -89.8% |
Next Earnings Update | 27 Aug 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%
Aug 03There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump
Aug 02What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You
Mar 18Revenue & Expenses Breakdown
How Staidson (Beijing) BioPharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 394 | -354 | 256 | 382 |
31 Dec 23 | 364 | -399 | 247 | 412 |
30 Sep 23 | 441 | -227 | 258 | 355 |
30 Jun 23 | 471 | -268 | 281 | 402 |
31 Mar 23 | 491 | -221 | 293 | 365 |
01 Jan 23 | 549 | -197 | 312 | 363 |
30 Sep 22 | 541 | -166 | 309 | 382 |
30 Jun 22 | 559 | -160 | 319 | 380 |
31 Mar 22 | 592 | -142 | 338 | 363 |
31 Dec 21 | 584 | -137 | 337 | 363 |
30 Sep 21 | 555 | -161 | 321 | 342 |
30 Jun 21 | 532 | -118 | 309 | 295 |
31 Mar 21 | 486 | -128 | 298 | 268 |
31 Dec 20 | 425 | -133 | 287 | 244 |
30 Sep 20 | 434 | -112 | 309 | 192 |
30 Jun 20 | 483 | -83 | 354 | 181 |
31 Mar 20 | 544 | -25 | 393 | 163 |
31 Dec 19 | 661 | 27 | 439 | 161 |
30 Sep 19 | 696 | 56 | 452 | 155 |
30 Jun 19 | 706 | 73 | 455 | 142 |
31 Mar 19 | 705 | 106 | 441 | 128 |
31 Dec 18 | 806 | 134 | 519 | 121 |
30 Sep 18 | 937 | 158 | 620 | 106 |
30 Jun 18 | 1,124 | 217 | 697 | 139 |
31 Mar 18 | 1,331 | 251 | 884 | 117 |
31 Dec 17 | 1,388 | 263 | 957 | 92 |
30 Sep 17 | 1,476 | 278 | 1,063 | 64 |
30 Jun 17 | 1,493 | 281 | 1,144 | 0 |
31 Mar 17 | 1,455 | 270 | 1,114 | 0 |
31 Dec 16 | 1,403 | 257 | 1,066 | 0 |
30 Sep 16 | 1,364 | 241 | 1,022 | 0 |
30 Jun 16 | 1,307 | 220 | 988 | 0 |
31 Mar 16 | 1,293 | 216 | 979 | 0 |
31 Dec 15 | 1,248 | 211 | 945 | 0 |
30 Sep 15 | 1,199 | 245 | 892 | 0 |
30 Jun 15 | 1,154 | 244 | 856 | 0 |
31 Mar 15 | 1,110 | 210 | 845 | 0 |
31 Dec 14 | 1,093 | 195 | 854 | 0 |
30 Sep 14 | 1,035 | 118 | 879 | 0 |
30 Jun 14 | 968 | 74 | 868 | 0 |
31 Mar 14 | 923 | 97 | 796 | 0 |
31 Dec 13 | 893 | 110 | 743 | 0 |
30 Sep 13 | 869 | 150 | 663 | 0 |
Quality Earnings: 300204 is currently unprofitable.
Growing Profit Margin: 300204 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300204 is unprofitable, and losses have increased over the past 5 years at a rate of 50.6% per year.
Accelerating Growth: Unable to compare 300204's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300204 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.6%).
Return on Equity
High ROE: 300204 has a negative Return on Equity (-34.39%), as it is currently unprofitable.